HEATHER MARTIN SCHWARTZ TRIAL

After that, subjects will be seen every three months. Subjects will be seen frequently by the Study Physician right after receiving their T cellsīack and up to first 6 months. Once the target cellĭose is determined, additional subjects will be enrolled to further test the safety and The study will evaluate threeĭifferent cell dose levels in order to find out the target cell dose. Purpose of this study is to test the safety of genetically changed T cells and find out whatĮffects, if any, they have in subjects with lung cancer. When the MAGE A10ᶜ⁷⁹⁶T cells are available, subjects will receive lymphodepletingĬhemotherapy with cyclophosphamide and fludarabine, followed by the T cell infusion. T cells that have been genetically changed with the aim of attacking and destroying cancer The changed T cells used in this study will be the subject's own The subject's T cells, which are a natural type of immune cell in the blood, and send them toĪ laboratory to be modified. Lymphodepleting chemotherapy regimen using a 3+3 dose escalation design.

HEATHER MARTIN SCHWARTZ TRIAL

This trial is a doseĮscalation trial that will evaluate 3 doses of transduced cells administered after a Is a study for subjects who have a blood test positive for HLA-A*02:01 and/or HLA-A*02:06 andĪ tumor test positive for MAGE A10 protein expression (protein or gene). Have advanced lung cancer which has grown or returned after being treated. This first time in human study is intended for men and women at least 18 years of age who Work with Max Diehn on circulating tumor DNA is leading towards the potential to improve surveillance and early detection of NSCLC amongst other applications. Wakelee is also involved in several collaborative efforts with her colleagues in thoracic surgery, radiation oncology, pulmonary medicine, basic science and population sciences.

Wakelee has developed 2 clinical trials in this patient population and is involved in translational efforts with the disease. Thymic malignancies are an understudied rare disease and Dr. Wakelee also plays a leadership role in the International Association for the Study of Lung Cancer (IASLC) having served on the board of directors from 2015-2019) and was elected to the role of President-Elect in 2019 and her tenure as President stared in 2021. Stanford University actively participates in trial design and recruitment of patients to ECOG-ACRIN trials. Wakelee is an active member of the Eastern Cooperative Oncology Group (ECOG-ACRIN). The treatment of NSCLC revolves increasingly around the use of immune modulatory agents, particularly PD-(L)1 checkpoint inhibitors and the majority of current trials utilize these drugs including bringing them to patients with earlier stages of disease with a hope to improve cure rates. Earlier work on anti-angiogenesis agents continues as well. Along with her other colleagues in thoracic medical oncology at Stanford she is focused on clinical trials with agents that are specifically targeted to known mutations in lung cancer such as EGFR, ALK and other 'driver' mutations with a particular focus on resistance mechanisms. Wakelee is a clinical investigator with a focus in lung cancer and other thoracic malignancies.

Vice Provost for Undergraduate Educationĭr.

Office of Vice President for Business Affairs and Chief Financial Officer.

Office of VP for University Human Resources.Stanford Woods Institute for the Environment.Stanford Institute for Economic Policy Research (SIEPR).Institute for Stem Cell Biology and Regenerative Medicine.Institute for Human-Centered Artificial Intelligence (HAI).Institute for Computational and Mathematical Engineering (ICME).Freeman Spogli Institute for International Studies.

Stanford Doerr School of Sustainability.

Heather martin schwartz